Previous close | 589,000.00 |
Open | 0.00 |
Bid | 530,100.00 x N/A |
Ask | 647,900.00 x N/A |
Day's range | 589,000.00 - 589,000.00 |
52-week range | 589,000.00 - 589,000.00 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 20 May 2024 |
1y target est | N/A |
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments. Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.